Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of OCH-NCNP1 in Patients With Relapsing Multiple Sclerosis
Conditions
Interventions
OCH-NCNP1
Placebo
Locations
1
Japan
National Center of Neurology and Psychiatry
Tokyo, Japan
Start Date
December 6, 2019
Primary Completion Date
May 31, 2023
Completion Date
May 31, 2023
Last Updated
November 9, 2023
NCT06276634
NCT05359653
NCT06138132
NCT06390930
NCT03401879
NCT06389968
Lead Sponsor
National Center of Neurology and Psychiatry, Japan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions